{"id":2584,"date":"2017-01-30T17:06:00","date_gmt":"2017-01-30T17:06:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2584"},"modified":"2025-01-15T03:34:06","modified_gmt":"2025-01-15T03:34:06","slug":"chronic-hepatitis-c-burden-and-care-cascade-in-australia-in-the-era-of-interferon-based-treatment","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/chronic-hepatitis-c-burden-and-care-cascade-in-australia-in-the-era-of-interferon-based-treatment\/","title":{"rendered":"Fardeau de l'h\u00e9patite C chronique et cascade de soins en Australie \u00e0 l'\u00e8re du traitement \u00e0 base d'interf\u00e9ron"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Contexte et objectif<\/h3>\n\n\n\n

Des r\u00e9gimes antiviraux \u00e0 action directe sans interf\u00e9ron pour l'infection par le virus de l'h\u00e9patite C (VHC) ont \u00e9t\u00e9 r\u00e9cemment disponibles en Australie, ouvrant une nouvelle \u00e8re dans la gestion clinique et de sant\u00e9 publique de l'infection par le VHC. Cette \u00e9tude a fourni des estimations actualis\u00e9es de la cascade et du fardeau des soins li\u00e9s \u00e0 l'infection par le VHC en Australie en tant que plateforme fiable pour \u00e9valuer l'impact futur des th\u00e9rapies sans interf\u00e9ron.<\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

Une approche de mod\u00e9lisation a \u00e9t\u00e9 appliqu\u00e9e pour estimer le nombre d'individus vivant avec une infection chronique par le VHC et avec divers stades de maladie h\u00e9patique. Les donn\u00e9es des registres nationaux de notification du VHC et de transplantation h\u00e9patique, la revue de la litt\u00e9rature et le consensus d'experts ont \u00e9clair\u00e9 les param\u00e8tres du mod\u00e8le. La notification du VHC et les donn\u00e9es du r\u00e9gime de prestations pharmaceutiques ont \u00e9t\u00e9 utilis\u00e9es pour estimer le nombre d'individus diagnostiqu\u00e9s pour le VHC et le recours au traitement.<\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

En 2014, environ 230470 personnes (fourchette: 180490 \u00e0 243 990) vivaient avec le VHC, parmi lesquelles 75% ont \u00e9t\u00e9 diagnostiqu\u00e9es (n = 172720; fourchette: 156 720-188 770), 20% avaient d\u00e9j\u00e0 re\u00e7u un traitement (n = 45 000; intervalle: 39280-50 720) et 11% avaient \u00e9t\u00e9 gu\u00e9ris (n = 24750; intervalle: 21520-27 990). Parmi les personnes infect\u00e9es par le VHC, la proportion de personnes au stade de fibrose h\u00e9patique \u2265F3 a doubl\u00e9 au cours de la derni\u00e8re d\u00e9cennie, passant de 9% (n = 18580) en 2004 \u00e0 19% (n = 44 730) en 2014. Les personnes qui ont commenc\u00e9 un traitement anti-VHC ont augment\u00e9 de 1100 en 1997 \u00e0 3840 en 2007, plafonn\u00e9 jusqu'en 2010 et diminu\u00e9 \u00e0 2790 en 2014.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Le fardeau des maladies h\u00e9patiques li\u00e9es au VHC a consid\u00e9rablement augment\u00e9. M\u00eame si la proportion diagnostiqu\u00e9e \u00e9tait \u00e9lev\u00e9e, le recours au traitement est rest\u00e9 faible, sans augmentation au cours des 7 derni\u00e8res ann\u00e9es. La r\u00e9duction du fardeau du VHC en Australie n\u00e9cessite une intensification des th\u00e9rapies anti-VHC sans interf\u00e9ron.<\/p>\n\n\n\n

Des pays:<\/strong> Australie<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background and aim Interferon-free direct-acting antiviral regimens for hepatitis C virus (HCV) infection have been recently available in Australia, beginning a new era in clinical and public health management of HCV infection. This study provided updated estimates of the HCV infection care cascade and burden in Australia as a reliable platform for assessing the […]<\/p>\n","protected":false},"author":24,"featured_media":3322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[1073,1077,768,535,771,706,769,1075,1074,494,1078,1076],"class_list":["post-2584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-alavi-m","publication-author-amin-j","publication-author-dore-gj","publication-author-estes-c","publication-author-gray-rt","publication-author-grebely-j","publication-author-hajarizadeh-b","publication-author-mcgregor-s","publication-author-mcmanus-h","publication-author-razavi-h","publication-author-sievert-w","publication-author-thompson-a"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2584"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2584\/revisions"}],"predecessor-version":[{"id":7568,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2584\/revisions\/7568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3322"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2584"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}